OrphoMed
ClosedOrphoMed is a biotech company in Bay Area, United States, founded in 2015. It has raised $41.8M across 2 rounds, most recently a $39.0M Series A in May 2017.
- Headquarters
- Bay Area, California
- Employees
- 1–10
- Founded
- 2015
- Business Model
- B2B
- Total Funding
- $41.8M
- Last Round
- $39.0M Series AMay 2017
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 5 investors for this company. The full record is or through the API.
About
OrphoMed is a clinical-stage biopharmaceutical company based in San Francisco, California focused on developing novel first-in-class dimer therapeutics. The company's pipeline targets gastrointestinal conditions including irritable bowel syndrome with diarrhea and opioid bowel dysfunction. OrphoMed received FDA Fast Track designation for its lead compound ORP-101 and reported positive Phase 2 results in 2022.
Summary
It lists 1–10 employees. It has raised $41.8M in total across 2 rounds, most recently a $39.0M Series A round in May 2017. Investors include New Enterprise Associates, Takeda (JP) and Pappas Capital.
Funding History
May 2017
Sign up to see all 2 events
Funding: Convertible Note through Series A. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/orphomed"><img src="https://indexed.vc/api/badge/company/orphomed" alt="OrphoMed on Indexed.vc" width="260" height="76" /></a>